1. Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program
- Author
-
Lore Decoster, Karin Pat, Anne Sibille, Frederic Clinckart, Sofie Joris, Stéphane Holbrechts, Marc Lambrechts, Frederique Bustin, Denis Schallier, Laurence Jacqmin, Wim Demey, Hassan Rezaei Kalantari, Veerle Surmont, Koen Deschepper, Thierry Pieters, Jean-Charles Goeminne, Medical Oncology, Clinical sciences, Laboratory of Molecular and Medical Oncology, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'oncologie médicale
- Subjects
Compassionate Use Trials ,medicine.medical_specialty ,Lung Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Non-small cell lung cancer ,Belgium ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,older ,Humans ,030212 general & internal medicine ,Adverse effect ,Lung cancer ,neoplasms ,non-small cell lung cancer ,Aged ,Retrospective Studies ,Performance status ,business.industry ,Age Factors ,Compassionate Use ,Retrospective cohort study ,medicine.disease ,Older ,Nivolumab ,Docetaxel ,030220 oncology & carcinogenesis ,oncology ,Non small cell ,Geriatrics and Gerontology ,business ,medicine.drug - Abstract
Objectives To compare real life effectiveness and safety of nivolumab in patients with non-small cell lung cancer (NSCLC), according to age and Eastern Cooperative Group performance status (ECOG-PS). Methods We performed a retrospective analysis of patients treated with nivolumab for NSCLC within a Belgian compassionate use program from July 2015 until December 2016. Safety and effectiveness were compared between patients aged ≥70 years and
- Published
- 2020